In the news release, Corgenix Reports Fiscal 2009 Financial Results, issued 25-Sep-2009 by Corgenix Medical Corporation over PR Newswire, we are advised by the company that in the Fiscal 2009 Conference Call Details paragraph, the conference call phone numbers should read "Corgenix invites all those interested in hearing management's discussion of fiscal year results to join a shareholders conference call on Friday, September 25, 2009 at 4:00 PM EST (2:00 PM MST). Interested parties can join the call by dialing (800) 894-5910. International participants may access the call by dialing +1 785 424-1052. The conference code is "CORGENIX". A replay will be available for 30 days following the call by dialing (800) 374-0934 for domestic participants and +1 402 220-0680 for international participants." rather than the incorrect phone numbers as originally issued inadvertently. The complete, corrected release follows: DENVER, Sept. 25 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC:CONX) (BULLETIN BOARD: CONX) , a worldwide developer and marketer of diagnostic test kits, today filed its fiscal year Form 10-K and reported financial results. The report disclosed that the company's operating results have advanced for the fiscal year ended June 30, 2009. Some of the results highlighted by the report are as follows: -- Total revenues for the year decreased $302,012 or 3.6% vs. the prior year. -- Total operating expenses decreased $107,869 or 2.2% vs. the prior year. -- Operating loss for the fiscal year was $349,490 vs. an operating loss of $602,279 for the prior year. -- Net loss for the year was $1,570,600 vs. $2,112,106 for the prior year. "While we were pleased with the improvement in operating income, net income and EBITDA this year due to our aggressive expense control program and the improvement in cost of goods, we were obviously disappointed with the decline in revenue," said Douglass Simpson, President and CEO of Corgenix. "In addition to the reduction of revenues from our contract manufacturing sector as previously reported, much of this was due to the impact of the overall global economy on our customers around the world as they tightened their expenditures and reduced their inventories." Mr. Simpson continued, "On the positive side, we will continue with our own belt-tightening as we move into the new fiscal year, and with the planned reduction in interest charges, will continue on the path to sustained profitability." The Company also indicated that it expects sales for fiscal 2010 to renew its previous growth trend. Fiscal 2009 Conference Call Details Corgenix invites all those interested in hearing management's discussion of fiscal year results to join a shareholders conference call on Friday, September 25, 2009 at 4:00 PM EST (2:00 PM MST). Interested parties can join the call by dialing (800) 894-5910. International participants may access the call by dialing +1 785 424-1052. The conference code is "CORGENIX". A replay will be available for 30 days following the call by dialing (800) 374-0934 for domestic participants and +1 402 220-0680 for international participants. About Corgenix Medical Corporation Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at http://www.corgenix.com/. Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements. SUMMARY OF FINANCIAL HIGHLIGHTS CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES OPERATIONAL DATA Fiscal Year Ended Fiscal Year Ended ----------------- ----------------- June 30, 2009 June 30, 2008 Net sales $8,063,557 $8,365,569 Gross profit $4,481,540 $4,336,620 Total operating expenses $4,831,030 $4,938,899 Operating loss $(349,490) $(602,279) Net loss $(1,570,600) $(2,112,106) EBITDA 403,903 83,616 Basic and diluted loss per share $(0.05) $(0.09) Weighted average shares outstanding 30,237,813 24,994,354 SUMMARY BALANCE SHEET DATA (in thousands) June 30, 2009 June 30, 2008 ------------- ------------- Cash $785 $1,521 Working capital 2,013 2,889 Total assets 6,906 7,888 Long-term debt 744 1,276 Total stockholders' equity 3,113 4,153 DATASOURCE: Corgenix Medical Corporation CONTACT: Company, William Critchfield, Senior VP and CFO of Corgenix Medical Corp, +1-303-453-8903, ; or Media, Dan Snyders, Vice President, Public Relations Supervisor of Armada Medical Marketing, +1-303-623-1190, ext. 230, , for Corgenix Medical Corp Web Site: http://www.corgenix.com/

Copyright